Biote Corp.
A maker of bioidentical hormone replacement therapy products, Biote Corp. trains and certifies doctors to implant tiny, grain-of-rice-sized hormone pellets under the skin, and supplies the kits, software, and marketing support their practices need. The company was founded in 2012 by OB/GYN Gary Donovitz, who turned to hormone therapy after seeing it transform a patient's life, and went public in 2022. Its name is a mashup of "bioidentical" and "testosterone."
Class A Common Stock
Bought 1.55M
Bought 75.0K
Bought 38.1K
Bought 107.8K
Granted 32.5K
Granted 24.6K
Bought 37.6K
Granted 44.3K · Sold 44.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Barrera Richard R +3 co-filers10% owner · 15 transactions | — | 8.79Mas of May 2025 | — | 1.55M | — |
| Heyer Andrew RDirector · 2 transactions | — | 2.29Mas of Mar 2025 | — | 75.0K | — |
| Cone Stephen MarkDirector · 1 transaction | +31% | 160.8Kas of Mar 2025 | — | 38.1K | — |
| Beer Marc DDirector · 1 transaction | — | 107.8Kas of Mar 2025 | — | 107.8K | — |
| Morris Debra LDirector · 2 transactions | +138.5% | 71.6K | 32.5K | — | — |
| Jacoby Dana LynnDirector · 2 transactions | +62.4% | 64.0Kas of May 2025 | 24.6K | — | — |
| Christensen BretChief Executive Officer, Director · 1 transaction | — | 37.6Kas of Mar 2025 | — | 37.6K | — |
| Peterson Robert CharlesChief Financial Officer · 3 transactions | — | 0as of Sep 2024 | 44.3K | — | 44.3K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +1.77M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.